Adolor 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) December 22, 2004
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (484) 595-1500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 1.01. Entry into a Material Definitive Agreement.
On December 22, 2004, Adolor Corporation, a Delaware corporation (the Company), entered Amendment No. 2 (the Amendment) to the Collaboration Agreement, dated April 14, 2002 (the Collaboration Agreement), between the Company and Glaxo Group Limited (GSK). The Collaboration Agreement provides for the exclusive worldwide development and commercialization of Entereg. Since entering into the Collaboration Agreement, the Company and GSK have worked jointly to promote the development of Entereg. The Amendment further clarifies the parties rights and obligations concerning marketing activities.
The description of the Amendment is qualified in its entirety by reference to Exhibit 10.1 to this Report.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: February 25, 2004